US 12,404,336 B2
Bispecific antagonist comprising a LAG-3 binding domain
Jackie Sheng, Thousand Oaks, CA (US); Margaret Karow, Santa Rosa Valley, CA (US); and Wei Zhang, Thousand Oaks, CA (US)
Assigned to GENSUN BIOPHARMA, INC., Newbury Park, CA (US)
Filed by GENSUN BIOPHARMA, INC., Newbury Park, CA (US)
Filed on Apr. 25, 2023, as Appl. No. 18/306,562.
Application 18/306,562 is a continuation of application No. 16/795,804, filed on Feb. 20, 2020, granted, now 11,667,716.
Application 16/795,804 is a continuation of application No. 16/457,421, filed on Jun. 28, 2019, granted, now 10,597,453.
Claims priority of provisional application 62/823,989, filed on Mar. 26, 2019.
Claims priority of provisional application 62/691,658, filed on Jun. 29, 2018.
Prior Publication US 2023/0331857 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 14/00 (2006.01); C07K 14/71 (2006.01); C07K 16/22 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2863 (2013.01) [A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/71 (2013.01); C07K 16/22 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2318/10 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)] 20 Claims
 
1. A polynucleotide encoding a bispecific antagonist, wherein the bispecific antagonist comprises a first targeting domain and a second targeting domain:
wherein the first targeting domain binds specifically to human LAG-3 and comprises:
(1) an immunoglobulin HCVR comprising three HCDRs: HCDR1, HCDR2 and HCDR3, wherein the HCDR 1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 163, 166 and 169, wherein the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 164, 167 and 170, and wherein the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 165, 168 and 171; and
(2) an immunoglobulin LCVR comprising three LCDRs: LCDR1, LCDR2 and LCDR3, wherein the LCD R 1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 172, 175 and 177, wherein the LCDR 2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 173 and 178, and wherein the LCDR 3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS; 174, 176 and 179.